RxDoctor Payments Data

John Kim, MD

Gastroenterology · Potsdam, NYNPI 1194828517

Payments from drug & device makers

$2,488in general payments, 2019–2025

Across 79 payments — averaging $31.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$280
  • Takeda Pharmaceuticals U.S.A., Inc.$270
  • Gilead$197
  • Cook Medical LLC$112
  • Lilly USA, LLC$106
  • plus $436 from 9 others

What the payments were for

  • Food & beverage$2,38996%
  • Education$994%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,488 in reported general payments places this provider in the 50th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$92,097
Medicare patients
458
Services billed
817

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi On-BodyRisankizumab-Rzaa13$244,230
XifaxanRifaximin63$194,213
RezdiffraResmetirom19$90,398
Humira(Cf) PenAdalimumab11$76,141
LinzessLinaclotide108$60,858
CreonLipase/Protease/Amylase35$52,653
Mesalamine90$46,182
Budesonide ErBudesonide13$14,853
Ursodiol65$11,113
Mesalamine ErMesalamine27$6,723
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates93$6,441
Budesonide DrBudesonide15$4,332
Mercaptopurine17$1,925
Sucralfate26$1,628
Nadolol29$1,467

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$15$194,21363 claims
AbbVieLinzess, Creon$1,087$113,511143 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Potsdam

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →